Compare HCM & HTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HCM | HTH |
|---|---|---|
| Founded | 2000 | 1998 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.2B |
| IPO Year | 2015 | 2003 |
| Metric | HCM | HTH |
|---|---|---|
| Price | $13.52 | $38.30 |
| Analyst Decision | Sell | Hold |
| Analyst Count | 1 | 2 |
| Target Price | $13.75 | ★ $37.50 |
| AVG Volume (30 Days) | 81.4K | ★ 188.2K |
| Earning Date | 03-05-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 2.13% |
| EPS Growth | N/A | ★ 51.72 |
| EPS | N/A | ★ 1.27 |
| Revenue | N/A | ★ $152,188,000.00 |
| Revenue This Year | $20.60 | N/A |
| Revenue Next Year | $15.62 | $3.22 |
| P/E Ratio | ★ $5.49 | $30.39 |
| Revenue Growth | N/A | ★ 15.52 |
| 52 Week Low | $9.77 | $30.78 |
| 52 Week High | $17.79 | $40.41 |
| Indicator | HCM | HTH |
|---|---|---|
| Relative Strength Index (RSI) | 63.47 | 45.65 |
| Support Level | $12.99 | $38.34 |
| Resistance Level | $15.54 | $38.52 |
| Average True Range (ATR) | 0.29 | 0.56 |
| MACD | 0.13 | -0.01 |
| Stochastic Oscillator | 68.12 | 41.82 |
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
Hilltop Holdings Inc is a Dallas-based financial holding company. The company has three segments: The banking segment includes the operations of the Bank; The broker-dealer segment includes the operations of Securities Holdings,; and the mortgage origination segment is composed of PrimeLending. Majority of revenue is from Broker-dealer Segment.